Meeting
2022 ASCO Annual Meeting
Comprehensive genomic profiling to identify gene alterations in DNA repair pathway across solid tumors.
Authors
Kevin McDonnell
City of Hope, Duarte, CA
Kevin McDonnell , Gargi D. Basu , Jess W. Hoag , David W. Hall , Fadel S. Alyaqoub , Susan M. Dombrowski , Pawan Noel , Szabolcs Szelinger , Sameer S. Udhane , Min Wang , Janine R. LoBello , Snehal Govind Thakkar , Frederick L. Baehner , Christine Hong , Wai Park , Gregory Idos , Stacy W. Gray , Stephen B. Gruber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3124)
DOI
10.1200/JCO.2022.40.16_suppl.3124
Abstract #
3124
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George
Poster
2023 ASCO Annual Meeting
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
First Author: Heidi Chwan Ko
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh